Fig. 5: Downregulation of TPX2 in CD8 + T cells promoted tumor growth, whereas TPX2 overexpression delayed tumor growth.
From: Downregulation of TPX2 impairs the antitumor activity of CD8+ T cells in hepatocellular carcinoma
A Illustration of the generation of HCC-specific CD8 + T cells (see details in the supplementary information) and adoptive CD8 + T cell transfer for the treatment of SMCC-7721-bearing NSG mice (n = 5). Naïve CD8 + T cells were isolated from the peripheral blood of healthy donors. B Illustration of CD8 + T cell transfer (i.v. 2 × 106 cells) and/or anti-PD-1 treatment (i.v.) at the indicated time points. Day-7 indicates the first day of subcutaneous SMCC-7721 cell inoculation. C Tumor growth in mice bearing SMCC-7721 cells was monitored via in vivo bioluminescence imaging with the IVIS imaging system (n = 5). anti-PD-1 antagonist antibody targeting PD-1, APC antigen-presenting cell, DC dendritic cell, HCC hepatocellular carcinoma, LV-NC lentivirus used as a control, LV-shRNA lentivirus used to knock down the human TPX2 gene, LV-TPX2 lentivirus used to overexpress the human TPX2 gene, MFI mean fluorescence intensity, PDX patient-derived xenograft, TNF-α tumor necrosis factor alpha, TIL tumor-infiltrating lymphocyte.
